Genmab A/S
Stock Forecast, Prediction & Price Target
Genmab A/S Financial Estimates
Genmab A/S Revenue Estimates
Genmab A/S EBITDA Estimates
Genmab A/S Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $8.48B N/A | $14.59B 72.07% | $16.47B 12.87% | Avg: $23.61B Low: $22.66B High: $24.44B avg. 43.37% | Avg: $28.30B Low: $26.79B High: $29.69B avg. 19.84% | Avg: $33.25B Low: $31.48B High: $34.88B avg. 17.49% | Avg: $39.41B Low: $37.31B High: $41.34B avg. 18.51% |
Net Income
% change YoY
| $2.95B N/A | $5.45B 84.37% | $4.35B -20.17% | Avg: $6.54B Low: $4.62B High: $12.43B avg. 50.36% | Avg: $8.32B Low: $6.22B High: $10.41B avg. 27.18% | Avg: $1.15B Low: $1.07B High: $1.22B avg. -86.14% | Avg: $1.52B Low: $1.41B High: $1.62B avg. 32.16% |
EBITDA
% change YoY
| $3.46B N/A | $7.04B 103.37% | $5.56B -21.04% | Avg: $11.53B Low: $11.06B High: $11.93B avg. 107.41% | Avg: $13.82B Low: $13.08B High: $14.50B avg. 19.84% | Avg: $16.24B Low: $15.37B High: $17.03B avg. 17.49% | Avg: $19.24B Low: $18.22B High: $20.19B avg. 18.51% |
EPS
% change YoY
| $46 N/A | $83.38 81.26% | $66.02 -20.82% | Avg: $98.69 Low: $70.14 High: $188.62 avg. 49.47% | Avg: $123.2 Low: $94.46 High: $157.95 avg. 24.83% | Avg: $17.5 Low: $16.28 High: $18.61 avg. -85.79% | Avg: $23.13 Low: $21.52 High: $24.6 avg. 32.16% |
Operating Expenses
% change YoY
| $5.46B N/A | $8.23B 50.76% | $10.92B 32.64% | Avg: $3.09B Low: $2.97B High: $3.20B avg. -71.64% | Avg: $3.71B Low: $3.51B High: $3.89B avg. 19.84% | Avg: $4.36B Low: $4.12B High: $4.57B avg. 17.49% | Avg: $5.17B Low: $4.89B High: $5.42B avg. 18.51% |
FAQ
What is Genmab A/S stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 5.89% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is 4.62B, average is 6.54B and high is 12.43B.
What is Genmab A/S stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 24.80% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $22.66B, average is $23.61B and high is $24.44B.
What is Genmab A/S stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 5.17% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is $70.14, average is $98.69 and high is $188.62.
What is the best performing analyst?
In the last twelve months analysts have been covering Genmab A/S stock. The most successful analyst is Raghuram Selvaraju.